EZH2 and prostate carcinoma: This paradigm of a dual function of a chromatin modifier within the same cell context has been previously reported for Enhancer of Zeste 2 (EZH2), a transcriptional repressor, whereby EZH2 and H3K27Ac, an activating mark, were found to co-occupy the promoter and activate the transcription of the androgen receptor gene in a methyltransferase-independent manner in prostate cancer cell lines16.